Richard Malamut

Articles

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.

News

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.